{"id":"leukapheresis","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04665076","NCT04503980","NCT06191887","NCT06938334","NCT03164265","NCT00861406","NCT07045909","NCT06446128","NCT04489862","NCT00039689","NCT07148791","NCT01110135","NCT06469710","NCT02248532","NCT03601442","NCT03378102","NCT01241682","NCT03207854","NCT03175380","NCT06550141","NCT01087515","NCT03406715","NCT01553214","NCT07261657","NCT02687672","NCT03532217","NCT02535364","NCT03744676","NCT04817345","NCT03657966","NCT06158828","NCT03649529","NCT01458288","NCT05625594","NCT00064337","NCT00024466","NCT04224558","NCT04844866","NCT00011505","NCT06572631","NCT00049218","NCT00586690","NCT07137494","NCT05075837","NCT00333892","NCT03344367","NCT04373941","NCT06823713","NCT04356469","NCT03166254"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Leukapheresis","companyId":"h-lee-moffitt-cancer-center-and-research-institute","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"H. Lee Moffitt Cancer Center and Research Institute","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Leukapheresis","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04665076","phase":"NA","title":"Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors","status":"UNKNOWN","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","isPivotal":false,"enrollment":60,"indication":"Plasma Cell Tumors","completionDate":"2025-10-21"},{"nctId":"NCT04503980","phase":"EARLY/Phase 1","title":"An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","isPivotal":false,"enrollment":10,"indication":"Colorectal Cancer, Ovarian Cancer","completionDate":"2022-06"},{"nctId":"NCT06191887","phase":"Phase 1","title":"Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relaps","status":"RECRUITING","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":27,"indication":"B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia","completionDate":"2040-12-31"},{"nctId":"NCT06938334","phase":"Phase 1","title":"A Single-arm, Open-label, Phase I/II Clinical Trial of Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) Genetically Modified With a Lentiviral Vector (LVV) Encoding for the Human Programmed ","status":"NOT_YET_RECRUITING","sponsor":"Altheia Science","isPivotal":false,"enrollment":15,"indication":"Diabetes, Type I","completionDate":"2029-06-15"},{"nctId":"NCT03164265","phase":"Phase 1","title":"Safety and Preliminary Efficacy of Donor-derived Regulatory Dendritic Cell (DCreg) Infusion and Immunosuppression Withdrawal in Living Donor Liver Transplantation","status":"COMPLETED","sponsor":"Angus W. Thomson PhD DSc","isPivotal":false,"enrollment":16,"indication":"Living Donor Liver Transplantation","completionDate":"2024-07-15"},{"nctId":"NCT00861406","phase":"Phase 1","title":"An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected Stage II and III (N1a, N2a) Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":38,"indication":"Melanoma","completionDate":"2017-02-24"},{"nctId":"NCT07045909","phase":"Phase 2","title":"A Phase 2, Open-label, Multicenter Multi-cohort Study to Evaluate the Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"PETHEMA Foundation","isPivotal":false,"enrollment":30,"indication":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","completionDate":"2030-03-31"},{"nctId":"NCT06446128","phase":"EARLY/Phase 1","title":"A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)","status":"RECRUITING","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","isPivotal":false,"enrollment":20,"indication":"Non-Hodgkin Lymphoma, B-cell","completionDate":"2026-12-31"},{"nctId":"NCT04489862","phase":"EARLY/Phase 1","title":"An Exploratory Study of MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","isPivotal":false,"enrollment":10,"indication":"Non-small-cell Lung Cancer, Mesothelioma","completionDate":"2022-12"},{"nctId":"NCT00039689","phase":"N/A","title":"Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":750,"indication":"HIV","completionDate":""},{"nctId":"NCT07148791","phase":"Phase 2","title":"Exploratory Clinical Study of Anti-BCMA-CD19 CAR-T Cell Therapy for Relapsed/Refractory IgG4-Related Disease","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","isPivotal":false,"enrollment":9,"indication":"IgG4 Related Disease, B-cell Mediated Autoimmune Disorders","completionDate":"2029-12-31"},{"nctId":"NCT01110135","phase":"Phase 2","title":"A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)","status":"COMPLETED","sponsor":"University of Washington","isPivotal":false,"enrollment":43,"indication":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma","completionDate":""},{"nctId":"NCT06469710","phase":"N/A","title":"A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","isPivotal":false,"enrollment":50,"indication":"Prostate Cancer, Circulating Tumor Cell","completionDate":"2025-12-30"},{"nctId":"NCT02248532","phase":"Phase 2","title":"Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","isPivotal":true,"enrollment":66,"indication":"Dilated Cardiomyopathy, Heart Failure","completionDate":"2017-12"},{"nctId":"NCT03601442","phase":"N/A","title":"Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleuce","status":"AVAILABLE","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":0,"indication":"Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)","completionDate":""},{"nctId":"NCT03378102","phase":"EARLY/Phase 1","title":"Antigen Specific Adoptive T Cell Therapy for Refractory Opportunistic Adenovirus Infection After a Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Mari Dallas","isPivotal":false,"enrollment":20,"indication":"Allogeneic Hematopoietic Stem Cell Transplantation","completionDate":"2028-12"},{"nctId":"NCT01241682","phase":"Phase 1","title":"Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma","status":"COMPLETED","sponsor":"Erasmus Medical Center","isPivotal":false,"enrollment":10,"indication":"Malignant (Pleural) Mesothelioma","completionDate":"2012-10"},{"nctId":"NCT03207854","phase":"N/A","title":"Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls","status":"RECRUITING","sponsor":"University of Southern California","isPivotal":false,"enrollment":625,"indication":"Healthy Subject, Hematologic and Lymphocytic Disorder","completionDate":"2027-12-31"},{"nctId":"NCT03175380","phase":"EARLY/Phase 1","title":"Collection and Storage of Biological Samples Obtained by Leukapheresis for the Future Study of Immune Responses Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US (A-051)","status":"COMPLETED","sponsor":"Aeras","isPivotal":false,"enrollment":15,"indication":"Tuberculosis","completionDate":"2019-01-10"},{"nctId":"NCT06550141","phase":"Phase 2","title":"A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","isPivotal":false,"enrollment":28,"indication":"Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma","completionDate":"2027-08-01"},{"nctId":"NCT01087515","phase":"NA","title":"Development and Validation of Magnetic Cell Separations Techniques Using a Good Manufacturing Practice (GMP) Grade Manufacturing Process for Clinical Applications and Generation of Pre-clinical Data","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","isPivotal":false,"enrollment":20,"indication":"Asthma, Allergic Rhinitis","completionDate":"2011-11"},{"nctId":"NCT03406715","phase":"Phase 2","title":"Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","isPivotal":false,"enrollment":14,"indication":"Small Cell Lung Cancer, Lung Cancer","completionDate":"2022-05-16"},{"nctId":"NCT01553214","phase":"Phase 4","title":"Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","isPivotal":false,"enrollment":1000,"indication":"Allogeneic Granulocyte Donation","completionDate":"2032-01-01"},{"nctId":"NCT07261657","phase":"EARLY/Phase 1","title":"A Pilot Trial of N-803 in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","isPivotal":false,"enrollment":8,"indication":"Myxoid Liposarcoma, Round Cell Liposarcoma","completionDate":"2032-09-02"},{"nctId":"NCT02687672","phase":"Phase 2","title":"Transplantation of Purified Autologous Bone Marrow- or Leukapheresis-Derived CD34+ and CD133+ for Patients With Spinal Cord Injuries: A Long-Term Comparative Evaluation of Safety and Efficacy Study.","status":"UNKNOWN","sponsor":"Stem Cells Arabia","isPivotal":false,"enrollment":50,"indication":"Spinal Cord Injury","completionDate":"2021-12"},{"nctId":"NCT03532217","phase":"Phase 1","title":"A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":19,"indication":"Metastatic Hormone-Sensitive Prostate Cancer","completionDate":"2022-07-25"},{"nctId":"NCT02535364","phase":"Phase 2","title":"A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","isPivotal":false,"enrollment":82,"indication":"Acute Lymphoblastic Leukemia","completionDate":"2017-09-01"},{"nctId":"NCT03744676","phase":"Phase 2","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","isPivotal":false,"enrollment":104,"indication":"Lymphoma, Non-Hodgkin, Lymphoma","completionDate":"2023-09-22"},{"nctId":"NCT04817345","phase":"Phase 2","title":"Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor","status":"WITHDRAWN","sponsor":"St. Jude Children's Research Hospital","isPivotal":false,"enrollment":0,"indication":"Sickle Cell Disease","completionDate":"2023-04"},{"nctId":"NCT03657966","phase":"Phase 2","title":"An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epit","status":"COMPLETED","sponsor":"SOTIO a.s.","isPivotal":false,"enrollment":33,"indication":"Ovarian Cancer Recurrent","completionDate":"2021-02-25"},{"nctId":"NCT06158828","phase":"Phase 1","title":"A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":68,"indication":"AML, Childhood, Aml","completionDate":"2030-05-31"},{"nctId":"NCT03649529","phase":"EARLY/Phase 1","title":"Adoptive Immunotherapy for HLA_A2 Genotype gp100 Positive Malignant Melanoma With GPA-TriMAR-T Cell","status":"UNKNOWN","sponsor":"Timmune Biotech Inc.","isPivotal":false,"enrollment":6,"indication":"Malignant Melanoma","completionDate":"2022-01-01"},{"nctId":"NCT01458288","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"GPCR Therapeutics, Inc.","isPivotal":false,"enrollment":12,"indication":"Multiple Myeloma, Non-hodgkin's Lymphoma","completionDate":"2013-07"},{"nctId":"NCT05625594","phase":"Phase 1","title":"A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With CNS Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":20,"indication":"Central Nervous System Lymphoma","completionDate":"2026-05-21"},{"nctId":"NCT00064337","phase":"Phase 2","title":"S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Ligh","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":104,"indication":"Multiple Myeloma, Plasma Cell Myeloma","completionDate":"2015-11"},{"nctId":"NCT00024466","phase":"Phase 1","title":"Vaccination In Peripheral Stem Cell Transplant Setting For Multiple Myeloma: The Use Of Autologous Tumor Cells/An Allo PSCT","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":28,"indication":"Multiple Myeloma","completionDate":"2009-04"},{"nctId":"NCT04224558","phase":"Phase 1","title":"Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","isPivotal":false,"enrollment":15,"indication":"Crohn Disease","completionDate":"2027-09-30"},{"nctId":"NCT04844866","phase":"Phase 2","title":"A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Miltenyi Biomedicine GmbH","isPivotal":false,"enrollment":45,"indication":"Diffuse Large B-cell Lymphoma","completionDate":"2031-09-30"},{"nctId":"NCT00011505","phase":"Phase 2","title":"Investigation of G-CSF-Induced Stem Cell Mobilization Potential in Patients With Diamond-Blackfan Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":false,"enrollment":15,"indication":"Diamond Blackfan Anemia","completionDate":"2006-04"},{"nctId":"NCT06572631","phase":"Phase 1","title":"Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: An Adoptive Cellular Therapy for Patients With Relapsed or Refractory AML or MDS Following an","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":0,"indication":"Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome","completionDate":"2026-12-12"},{"nctId":"NCT00049218","phase":"Phase 1","title":"A Phase I-II Trial Using Dendritic Cells Transduced With An Adenoviral Vector Containing The p53 Gene To Immunize Patients With Extensive Stage Small Cell Lung Cancer After Standard Chemotherapy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","isPivotal":false,"enrollment":56,"indication":"Lung Cancer","completionDate":"2014-05"},{"nctId":"NCT00586690","phase":"Phase 1","title":"Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions(DLI) From 6/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (A","status":"COMPLETED","sponsor":"David Rizzieri, MD","isPivotal":false,"enrollment":47,"indication":"Lymphoma","completionDate":"2013-11"},{"nctId":"NCT07137494","phase":"Phase 1","title":"A Phase I Study of MB-CART19.1 Cellular Therapy for Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) Using On- Site Manufacturing With the CliniMACS Prodigy Device","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":12,"indication":"Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma","completionDate":"2028-08"},{"nctId":"NCT05075837","phase":"Phase 1","title":"Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation(HSCT)","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","isPivotal":false,"enrollment":10,"indication":"Viral Infection After HSCT","completionDate":"2025-07-25"},{"nctId":"NCT00333892","phase":"N/A","title":"Leukapheresis Procedures to Obtain Lymphocytes for Research Studies on Antiretroviral Naive HIV-infected Patients","status":"COMPLETED","sponsor":"Canadian Immunodeficiency Research Collaborative","isPivotal":false,"enrollment":220,"indication":"Human Immunodeficiency Virus","completionDate":"2008-12"},{"nctId":"NCT03344367","phase":"Phase 1","title":"A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)","status":"UNKNOWN","sponsor":"Peking University","isPivotal":false,"enrollment":20,"indication":"Non Hodgkin Lymphoma","completionDate":"2022-03"},{"nctId":"NCT04373941","phase":"Phase 2","title":"Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia: Part II of a Prospective, Randomized Controlled, Multi-Institutional Trial","status":"UNKNOWN","sponsor":"Holterman, Ai-Xuan, M.D.","isPivotal":false,"enrollment":400,"indication":"Biliary Atresia","completionDate":"2025-10-31"},{"nctId":"NCT06823713","phase":"Phase 1","title":"An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERA","status":"RECRUITING","sponsor":"Resolution Therapeutics Limited","isPivotal":false,"enrollment":30,"indication":"End-stage Liver Disease (ESLD), Cirrhosis, Liver","completionDate":"2028-11-29"},{"nctId":"NCT04356469","phase":"Phase 2","title":"Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Non-Malignant Hematological Disorders in Children","status":"RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","isPivotal":false,"enrollment":17,"indication":"Hemoglobinopathy (Disorder), Severe Aplastic Anemia","completionDate":"2026-06-30"},{"nctId":"NCT03166254","phase":"Phase 1","title":"Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive St","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":0,"indication":"Non Small Cell Lung Cancer, NSCLC","completionDate":"2027-05-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":76,"withResults":10},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}